|
|
||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Fri., Apr. 26, 11:02 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||
Corporate Bonds| This Slide: #7 of 25 |
Slide #7. Supernus Pharmaceuticals, Inc. — Corporate Bonds
Company:
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
$Amount Offered:
$75,000,000
Date of Pricing:
4/26/2013
Bond Offering Details:
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") today announced the pricing of its offering of $75.0 million aggregate principal amount of Convertible Senior Secured Notes due 2019 (the "Convertible Notes") in a private offering under the Securities Act of 1933, as amended (the "Securities Act"). Supernus also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15.0 million aggregate principal amount of the Convertible Notes. The sale of the Convertible Notes is expected to close on May 3, 2013, subject to customary closing conditions.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
SUPN SEC Filing Email Alerts Service
Open the SUPN Page at The Online Investor »
|
|||||||||||||||||||||
Open the SUPN Page at The Online Investor (in a new window) »
 Free SUPN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Strong Buy (3.50 out of 4) 56th percentile
(ranked higher than approx. 56% of all stocks covered)
Analysts' Target Price: SUPN Stock Forecast Based on Zacks ABR data; powered by Xignite |
Corporate Bonds | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.